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Psoriasis (PS) and Crohn disease (CD) have been shown to be epidemiologically, pathologically, and therapeutically connected, but little
is known about their shared genetic causes. We performedmeta-analyses of five published genome-wide association studies on PS (2,529
cases and 4,955 controls) and CD (2,142 cases and 5,505 controls), followed up 20 loci that showed strongest evidence for shared disease
association and, furthermore, tested cross-disease associations for previously reported PS and CD risk alleles in additional 6,115 PS cases,
4,073 CD cases, and 10,100 controls. We identified seven susceptibility loci outside the human leukocyte antigen region (9p24 near
JAK2, 10q22 at ZMIZ1, 11q13 near PRDX5, 16p13 near SOCS1, 17q21 at STAT3, 19p13 near FUT2, and 22q11 at YDJC) shared between
PS and CD with genome-wide significance (p< 53 108) and confirmed four already established PS and CD risk loci (IL23R, IL12B, REL,
and TYK2). Three of the shared loci are also genome-wide significantly associated with PS alone (10q22 at ZMIZ1, prs1250544 ¼
3.53 3 108, 11q13 near PRDX5, prs694739 ¼ 3.71 3 1009, 22q11 at YDJC, prs181359 ¼ 8.02 3 1010). In addition, we identified one
susceptibility locus for CD (16p13 near SOCS1, prs4780355 ¼ 4.99 3 108). Refinement of association signals identified shared genome-
wide significant associations for exonic SNPs at 10q22 (ZMIZ1) and in silico expression quantitative trait locus analyses revealed that
the associations at ZMIZ1 and near SOCS1 have a potential functional effect on gene expression. Our results show the usefulness of joint
analyses of clinically distinct immune-mediated diseases and enlarge the map of shared genetic risk loci.Introduction
Psoriasis (PS [MIM 177900]) and Crohn disease (CD [MIM
266600]) are both chronic inflammatory epithelial disorders
that are triggered by an activated cellular immune system
and have an estimated sibling relative risk (ls) of 4–11
1,2
and 25–42,3 respectively, and a prevalence of 2%–3% and
about 0.1%, respectively, in populations of European
ancestry.4,5 PS is a common hyperproliferative disorder of
the skin, characterized by red scaly plaques, typically occur-
ringon the elbows, knees, scalp, and lowerback.6 Incontrast,
CD is primarily a gut disorder affecting any aspect of the
gastrointestinal tract butwith extraintestinalmanifestations
which might also affect the skin (e.g., erythema nodosum
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microflora, with host immune mechanisms in a genetically
susceptible host.8 Although PS and CD are clinically
distinct diseases, they are observed togethermore frequently
than expected by chance, which could indicate shared
genetic factors acting in the etiology of both diseases.9–11
Recently, several genome-wide association studies (GWASs)
have successfully been carried out separately for CD
and PS12–20 and identified shared susceptibility genes,
such as IL23R (MIM 607562), IL12B (MIM 161561),
REL (MIM 164910), and TYK2 (MIM 176941), thereby
providing further evidence for a genetic overlap of
both diseases.13,16,21–23 One of the best characterized
risk loci for bothCDandPS is IL23R, located in a drug-target-
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Figure 1. Study Design for the Combined
Analysis of CD and PS
For discovery, we conducted a PS and a CDGWAS
meta-analysis (panel A and B in Table S1), respec-
tively, and employed two strategies (OVERLAP
and COMBINED) to systematically search for
shared risk loci. In a first approach (OVERLAP),
we tested established non-HLA PS risk SNPs for
potential association (p < 0.01) with CD and
vice versa. In a second approach (COMBINED),
we selected SNPs from 20 loci for being nomi-
nally associated in each of the single-disease
meta-analyses (ppanel A < 0.05, ppanel B < 0.05)
and for being significantly associated in the
combined-phenotype association analysis at the
104 level (ppanel A&B < 10
4). For replication,
follow-up SNP genotyping was performed for
CD and PS in independent replication panels
(panels C–E in Table S1). The following abbrevia-
tions are used: PS-GER, German PS GWAS; PS-US,
United States PS GWAS; PS-Canada, Canadian
PS GWAS; CD-GER, German CD GWAS; and
CD-UK, United Kingdom CD GWAS. For each
panel, numbers of cases/controls are displayed
in parentheses.thought to be a key player driving autoimmunity in
human disease.25 A recent functional characterization of
the amino acid substitution R381Q in IL23R suggests that
IL-23-induced Th17 cell effector function is reduced in
protective allele carriers and leads to protection against
several autoimmune diseases, including PS, CD, and
ankylosing spondylitis.26
So far, shared susceptibility loci for CD and PS have been
identified by single-disease GWAS for CD or PS separately,
and established risk SNPs for one disease are usually tested
for association in another disease,27–31 rather than in a
combined systematic approach. Combined GWASs were
only conducted across clinically related phenotypes, such
as CD and ulcerative colitis (UC),32 CD and sarcoidosis
(SA)27 or CD and celiac disease (CelD).33 Recently, Zherna-
kova et al.34 performed a meta-analysis with a similar
systematic approach that combined genome-wide geno-
type data from two autoimmune diseases affecting dif-
ferent organs, namely CelD and rheumatoid arthritis
(RA). They identified eight shared risk loci outside the
human leukocyte antigen (HLA) region for CelD and RA,
four of them previously not known to be associated with
either CelD or RA. Based on genome-wide SNP data for
CelD and RA, the authors identified an increased proba-
bility for CelD risk SNPs to confer also an increase in risk
for RA and vice versa. Zhernakova et al.34 postulated
criteria for declaring a SNP as being a shared risk factor
for two clinically distinct diseases, namely that shared
SNPs (1) have to reach genome-wide significance in the
combined analysis of the initial GWAS screening stage
and the replication stage of the two distinct diseases
(pGWASþRepl < 5 3 10
8) and (2) have to achieve, for each
disease separately, nominal significance in the replication
stage (pRepl < 0.05) as well as pGWASþRepl < 10
3 in the
combined analysis of screening and replication stage.The AmWe used the criteria proposed by Zhernakova et al.34 in
a genome-wide association analysis combining CD and
PS to systematically identify shared risk loci associated
with both diseases. A two-fold strategy was employed: in
a first approach (OVERLAP), we tested established non-
HLA CD risk SNPs for association with PS and vice versa,
thereby seeking confirmation of whether known risk loci
for one disease also play a role in the etiology of the other
disease, disregarding the direction of effect. In a second
approach (COMBINED), we performed a meta-analysis for
the combined phenotype based on genome-wide data
sets of both CD and PS in order to increase power for the
detection of new shared risk alleles because of an increased
sample size. The latter approach allows consideration of
same-direction as well as opposing-direction allelic effects
of putative shared markers between CD and PS through
the use of suitable allele coding. We followed up 20 loci
that showed the strongest association in the COMBINED
approach and that had not been previously reported
as being risk factors for either CD or PS. Follow-up
was performed in independent replication panels from
Germany, Estonia, Italy, United Kingdom, and the United
States (see Table S1, available online).Subjects and Methods
Study Subjects
We analyzed a collection of different data sets. Figure 1 details the
different panels and their use in this study. For discovery, we
combined genome-wide case-control data of single-nucleotide
polymorphisms (SNP) for psoriasis (PS; panel A) and Crohn disease
(CD; panel B) (see Table S1) respectively, conducted genome-wide
meta-analyses on PS and CD, respectively, and employed two
strategies (COMBINED and OVERLAP, see below) to systematically
identify risk loci associated with both diseases. Replication waserican Journal of Human Genetics 90, 636–647, April 6, 2012 637
performed in independent replication panels from Germany (see
panels C–E), Estonia (panels C and D), Italy (panel E), United
Kingdom (panels C and E), and the United States (panel C) (see
Table S1). Written, informed consent was obtained from all study
participants and all protocols were approved by the institutional
ethical review committees of the participating centers.
Initial GWAS and German Replication Data
All German CD patients in discovery and replication panels (B and
C–E, respectively) were recruited either at the Department of
General Internal Medicine, Christian-Albrechts-University, Kiel,
and the Charite´ University Hospital, Berlin; through local outpa-
tient services; or nationwide with the support of the German
Crohn and Colitis Foundation. German PS cases in discovery
and replication panels (A and C andD, respectively) were recruited
either at the Department of Dermatology, Christian-Albrechts-
University, Kiel, or the Department of Dermatology and Allergy,
Technical University, Munich, or through local outpatient
services. Individuals were considered to be affected by PS if chronic
plaque or guttate psoriasis lesions covered more than 1% of the
total body surface area or if at least two skin, scalp, nail, or joint
lesions were clinically diagnosed as psoriasis. The 4,680 German
healthy control individuals in discovery and replication panels
(A–E) were obtained from the Popgen biobank.35 The additional
3,391 German healthy controls (after quality control measures)
in the discovery panels (A and B) were selected from the KORA
S3þS4 survey, an independent population-based sample from
the general population living in the region of Augsburg, southern
Germany.36 Another 674 German healthy controls in the
discovery panels (A and B) were selected from ISAAC Phase II
study.37 German GWAS controls of the discovery phase were
randomly assigned to panels A and B at equal proportions, while
ensuring that controls in panel A did not overlap with German
GWAS controls used in the independent genome-wide meta-anal-
ysis on CD.13 The Collaborative Association Study of Psoriasis
(CASP) samples14 consisted of 1,303 PS cases and 1,322 controls
after quality control measures and are part of panel A in our study.
The data sets used for the analyses described in this manuscript
were obtained from the database of Genotype and Phenotype
(dbGaP). The genotyping of samples was provided through the
Genetic Association Information Network (GAIN).38 The Cana-
dian samples (from Genizon BioSciences andM. Belouchi, unpub-
lished data) consisted of 757 PS cases and 987 controls sampled
from the Que´bec founder population (QFP) after quality control
measures. They are part of panel A. Membership in the QFP was
defined as having four grandparents with French-Canadian family
names who were born in the Province of Que´bec, Canada, or in
adjacent areas in the provinces of New Brunswick and Ontario
or in New England or New York state. This criterion assured that
all subjects were descendants of French-Canadians living before
the 1960s, after which time admixture with non-French-Cana-
dians became more common. CD cases and controls from the
United Kingdom were recruited from the 1958 birth cohort and
UK National Blood Service for the Welcome Trust Case Controls
Consortium (WTCCC) (described in details in WTCCC28). The
WTCCC1 CD samples consisted of 1,662 CD cases and 2,860
healthy controls after quality control procedures and entered the
analysis as part of panel B.
Additional Replication Data
Anumber of collaborative data sets were used as replication panels.
The Estonian samples used in the OVERLAP and COMBINED
approaches (part of panels C and D) were collected at the Depart-
ment of Dermatology and Venerology and at the Department of638 The American Journal of Human Genetics 90, 636–647, April 6, 2Physiology and Centre of Translational Medicine at the University
of Tartu.
Additional Estonian samples (part of panel C) used for replica-
tion in the OVERLAP approach consisted of samples provided by
the population-based biobank of the Estonian Genome Center,
University of Tartu. Subjects were recruited by general practi-
tioners (GP) and physicians in the hospitals. Participants in the
hospitals were randomly selected from individuals visiting GP
offices or hospitals. Diagnosis of PS on the basis of clinical symp-
toms was posed by a general practitioner and confirmed by
a dermatologist. At the moment of recruitment, the controls did
not report diagnosis of osteoarthritis, psoriasis, or autoimmune
diseases. The United States samples (part of panel C) used for repli-
cation in the OVERLAP approach consisted of 2,137 PS cases and
1,903 controls of white European ancestry from the United States.
The Italian samples (panel E) used in the COMBINED approach
consisted of 688 CD cases and 879 healthy controls that were
used in the independent genome-wide meta-analysis on CD.13
The psoriasis data set from the United Kingdom consisted of
2,178 PS cases collected through the Genetic Analysis of Psoriasis
Consortium (GAPC) and 2,657 controls from the WTCCC2
common control set, used as the GWAS discovery set described
in Strange et al. in 2010.16 Only controls that did not overlap
with WTCCC1 controls were used. UK cases and controls entered
the analysis as part of panel C and E.
Quality Control and Genome-wide Genotype
Imputation
Quality control (QC) was performed for each sample set separately.
In each sample set samples with more than 5% missing data
were excluded before genotype imputation. We also excluded
individuals from each pair of unexpected duplicates or relatives,
as well as outlier individuals with average marker heterozygosities
of55 standard deviation away from the samplemean. The remain-
ing samples were tested for population stratification with the
principal components stratification method as implemented in
EIGENSTRAT,39 and population outliers were subsequently
excluded. SNPs that hadmore than 5%missing data, aminor allele
frequency less than 1% or deviated from Hardy-Weinberg equilib-
rium (exact p < 104 in controls) per sample set were excluded
with thePLINKsoftwareversion1.07.40 SNP imputationwascarried
out with the BEAGLE v.3.1.141 software package and 690HapMap3
referencehaplotypes fromtheCEU,TSI,MEX, andGIHcohorts42 to
predict missing autosomal genotypes in silico. We subsequently
analyzed only those SNPs that could be imputed with moderate
confidence (INFO score r2 > 0.3) and had a minor allele frequency
more than 1% in cases or in controls. To take imputation uncer-
tainty into account, phenotypic association was tested for allele
dosage data separately for each of the five GWAS data sets in panels
AandB through theuseof PLINK’s logistic regression framework for
dosage data. To control potentially confounding effects due to pop-
ulation stratification, we adjusted for the top ten eigenvectors from
EIGENSTRAT in the regression analysis. The genomic inflation
factor l is defined as the ratio of the medians of the sample c2 test
statistics and the 1 degree of freedom c2 distribution (0.455).43
Because the estimated genomic inflation factor l scaleswith sample
size, it is informative to report the inflation factor for an equivalent
study of 1,000 cases and 1,000 controls (l1000) by rescaling l.
44
Meta-Analyses
Meta-analyses were performed with PLINK’s meta-analysis func-
tion and with its standard error of odds ratio weighting option012
(inverse variance weighting), which implicitly deals with imputa-
tion uncertainty. For the combined-phenotype analysis, we per-
formed two sorts of meta-analysis in order to detect associations
of SNPs with either the same or opposite allelic effects in the two
diseases. For the same-effect analysis, themeta-analysis was carried
out as usual. For the opposite-effect analysis, first we flippedminor
andmajor alleles of each biallelic SNP in the CD data sets tomimic
an opposite-direction effect of the allele in CD and performed
a meta-analysis afterward. For both effects models, we considered
only those SNPs whose genotypes were available from at least
four out of the five GWAS data sets in panels A and B.
Follow-Up Genotyping
Genotyping was carried out with our Sequenom iPlex plat-
form from Sequenom and TaqMan technology from Applied
Biosystems. Individuals with more than 3% missing data were
removed. SNPs that hadmore than 3%missing data, a minor allele
frequency less than 1% or deviated from Hardy-Weinberg
equilibrium (exact p < 104 in controls) per sample set were
excluded. p values for allele-based tests of phenotypic association
for each single-replication sample sets (panels C–E) were calcu-
lated with PLINK. PLINK’s meta-analysis function was used to
obtain p values for the replication data set (pRepl) and for the
combined discovery-replication data set (pGWASþRepl).
Regional Imputation Based on the 1000 Genomes
Project Reference
To enable imputation based on the 1000 Genomes project
data, SNPpositions referring toNCBIbuild36weremapped tobuild
37. SNP imputation was carried out with the BEAGLE software
package v.3.1.141 and 566 EUR (European) haplotypes generated
by the 1000 Genomes Project.45 We analyzed only imputed SNPs
with moderate imputation confidence (INFO score r2 > 0.3) and
a minor allele frequency more than1% in cases or in controls.
Gene Relationships across Implicated Loci Pathway
Analysis
The Gene Relationships Across Implicated Loci (GRAIL) software46
quantifies functional similarity between genes by applying
established statistical text mining methods to the PubMed
database of published scientific abstracts. As input we used
the following list of SNPs: rs2201841, rs2082412, rs702873,
rs12720356, rs10758669, rs694739, rs281379, rs181359,
rs4780355, rs744166, and rs1250544. GRAIL was run with the
following settings: HapMap release ¼ HapMap release 22/hg18;
HapMap population ¼ CEU (Utah residents with ancestry from
northern and western Europe from the Centre d0E´tude du Poly-
morphisme Humain collection); functional data source¼ PubMed
Text (April 2011); and gene size correction ¼ on. GRAIL output
results were visualized with VIZ-GRAIL.Results
Preparation of Single-Disease Meta-Analyses for
Discovery Phase by Means of HapMap3 Imputation
The overall study workflow for the combined analysis of
CD and PS is displayed in Figure 1. For discovery, we con-
ducted a meta-analysis on PS comprising 2,529 PS cases
and 4,955 controls from three previously published
GWASs,14,15 all of European descent (panel A in TableThe AmS1). SNP data were combined with genotype imputation
based on the HapMap3 reference. We subsequently used
standard meta-analysis methodology (see Subjects and
Methods). In total, 1,121,166 quality-controlled auto-
somal-imputed SNPmarkers were available for the analysis
on PS. To control for potential population stratification, we
adjusted association test statistics by means of principal
component analysis (PCA) (see Subjects and Methods). A
quantile-quantile (Q-Q) plot of the meta-analysis revealed
a marked excess of significant associations in the tail of
the distribution (Figure S1A), which is primarily due to
thousands of highly significant association signals from
the HLA region. Genetic heterogeneity was low; there
was an estimated genomic inflation factor of l1000 ¼
1.02743,44 (see Subjects and Methods). Results of the
meta-analysis on PS are summarized in Figure S2A.
In the same way, we performed ameta-analysis on CD by
using 1,034,639 quality-controlled autosomal-imputed
markers fromaGermanGWAS13 andapreviouslypublished
UK GWAS,28 consisting of 2,142 CD cases and 5,505
controls in total (panel B in Table S1). Again, we observed
low genomic inflation (l1000 ¼ 1.032, Figure S1B). Results
of the meta-analysis on CD are summarized in Figure S2B.
OVERLAP Approach: Cross-Disease Analysis of
Established Risk SNPs
So far, four established GWAS risk loci that are located
outside the HLA region and shared between CD and PS
have been reported in the literature, namely IL23R, IL12B,
REL, andTYK2 (Table 1). Although themarkers that showed
the strongest association differed between the two diseases
at each of the first three loci, we found the same SNP
rs12720356 at TYK2 to be associated with both CD and
PS. To seek confirmation of whether known risk loci for
CD also play a role in the etiology of PS and vice versa, we
checked whether markers that were significant (p < 0.01)
in our PS meta-analysis were among the 71 established
risk SNPs previously implicated inCD13 andwhether signif-
icant markers (p < 0.01) from our CD meta-analysis were
among the25 establishedPS risk SNPs.14–20 The four already
established shared risk SNPs (Table 1) were excluded. Given
the well-established and heterogeneous allelic associations
of the HLA region on chromosome 6 with both CD and
PS, we also excluded all markers from the extended HLA
region (chr6:25-34 Mb). Although none of the known PS
SNPs were significantly associated with CD in our analysis,
five out of the 71 known CD risk SNPs met our criterion
of significance, namely rs10758669 (JAK2 [MIM
147796]), rs694739 (PRDX5 [MIM 606583]), rs281379
(FUT2 [MIM 182100]), rs744166 (STAT3 [MIM 102582]),
and rs181359 (YDJC;HGNC 27158). We genotyped these
five SNPs by using TaqMan technology in a large indepen-
dent replication panel comprising 3,937 PS cases and
4,847 controls but also used summary statistics data of
the five SNPs from an independent GWAS on PS16
comprising 2,178 PS cases and 2,657 controls. The overall
replication panel consisted of 6,115 PS cases and 7,504erican Journal of Human Genetics 90, 636–647, April 6, 2012 639
Table 1. Established Risk Loci Shared between CD and PS from Published Studies on CD and PS, Respectively
Locus
Genes of
Interesta
Top CD
dbSNP IDb
Risk
Allele OR
Top PS
dbSNP IDb
Risk
Allele OR
LD between CD and
PS SNPs (D0/r2) Comment
1p31 IL23R rs11209026c G 2.66 rs2201841f G 1.13 1.0/0.018 different markers
5q33 IL12B rs6556412d A 1.18 rs2082412f G 1.44 0.715/0.269 different markers
2p16 REL rs10181042e T 1.14 rs702873g G 1.12 0.036/0.001 different markers
19p13 TYK2 rs12720356e G 1.12 rs12720356g T 1.40 same marker same marker, opposite
direction of effect
aCandidate genes of interest are listed for the locus.
bLead SNP with most significant association within a locus, as stated in the reference publication.
cSee Franke et al.13 and Duerr et al.21
dSee Barrett et al.12 and Franke et al.13
eSee Franke et al.13
fSee Cargill et al.22 and Nair et al.23
gSee Strange et al.16controls (panel C, Table S1). We performed single-marker
association tests for panel C (pPS-Repl) and conducted
a meta-analysis (pPS-GWASþRepl) by combining association
results from the GWAS (pPS-GWAS) and the replication
(pPS-Repl) stages (Table 2). All of the CD risk SNPs were
also significantly associated with PS at the previously
proposed level34 of pPS-Repl < 0.05 and pPS-GWASþRepl <
103 (rs10758669 near JAK2, rs694739 near PRDX5,
rs281379 near FUT2, and rs181359 at YDJC, rs744166
at STAT3). These five SNPs have already been reported
to show significant association at the genome-wide level
(pCD-GWASþRepl < 5 3 10
8, pCD-Repl < 0.05, and
pCD-GWASþRepl < 10
3) in a very large, independent
genome-wide meta-analysis on CD roughly three times
the size of this one, that is comprising 6,333 CD cases
and 15,056 controls.13 All five SNPs achieved genome-
wide significance in the combined analysis of PS discovery
panel A, PS replication panel C, and CD discovery data
from Franke et al.13 (pCDPS-GWASþRepl < 5 3 10
8). Further-
more, SNP rs694739, 7.9 kb downstream of PRDX5, as well
as SNP rs181359, 53.7 kb downstream of YDJC, reached
genome-wide significance for PS only (prs694739 ¼ 3.71 3
1009 and prs181359 ¼ 8.02 3 1010). We also observed
a highly significant association at the FUT2 locus
(prs281379 ¼ 7.86 3 1008) for PS only.
COMBINED Approach, Part 1: Meta-Analysis
Considering Same-Direction Effects
In order to identify additional shared genetic susceptibility
loci in CD and PS, we performed a meta-analysis of the
combined phenotype where CD and PS were considered
as a single phenotype. The disease-specific meta-analyses
(panels A and B) were merged to form a combined-pheno-
type meta-analysis discovery panel comprising 2,142 CD
cases, 2,529 PS cases, and 10,460 healthy controls. In total,
1,123,777 quality-controlled autosomal markers were
available for the analysis in at least four out of the five
GWAS data sets. As with the OVERLAP approach, we
excluded all markers from the extended HLA region
(chr6:25-34Mb), leaving 1,116,213 autosomal SNPs for
screening of shared risk loci. We observed only low640 The American Journal of Human Genetics 90, 636–647, April 6, 2genomic inflation for the same-direction meta-analysis
(l1000 ¼ 1.023; Figure S3A). After exclusion of established
loci for PS and CD, the inflation factors further decreased
(Figure S3C). To provide proof of principle for our
approach, we first examined association signals at the three
established shared risk loci with same-direction effects of
alleles for CD and PS (see Table 1). We observed highly
significant association signals for all three loci (pIL23R ¼
1.82 3 1022, pIL12B ¼ 3.32 3 107, and pREL ¼ 1.53 3
107; Figures S4A–S4C). Subsequently, we selected SNPs
for being nominally associated in each of the single-disease
meta-analyses (pCD-GWAS < 0.05, pPS-GWAS < 0.05) and for
being significantly associated in the combined-phenotype
association analysis at the 104 level (pCDPS-GWAS < 1 3
104). This resulted in 17 SNPs located at 17 distinct loci.
Except for the four known shared loci (see Table 1), we
did not exclude established risk loci from either CD or PS
to maintain the chance of detecting shared risk alleles at
these loci. Because one of the 17 SNPs is located at 10q22
(ZMIZ1 [MIM 607159]), which is an established CD risk
locus, we added the established CD-associated SNP
rs1250550 from this region to the list of follow-up SNPs.
We then genotyped these 18 SNPs in an independent panel
of 1,713 CD cases, 1,009 PS cases and 3,565 controls (panel
D, Table S1D) by using the Sequenom iPlex platform.
Association results for all 18 SNPs are shown in Table S2.
The strongest association was observed at ZMIZ1 for SNP
rs1250544 (pCDPS-GWAS¼ 1.123 105 and pCDPS-GWASþRepl¼
2.66 3 1010; see Table S2 and Figure S5A) and yielded
genome-wide significance in the same-effect combined-
phenotype analysis of discovery panels A andB and replica-
tion panel D. SNP rs1250544 reached also genome-wide
significance for PS alone (pPS-GWASþRepl ¼ 3.90 3 108). A
robust association with CD, but not with PS, was observed
at SOCS1 (MIM 603597) on chromosomal region 16p13
(pCDPS-GWAS ¼ 9.36 3 107, pCD-GWAS ¼ 1.47 3 103, and
pCD-GWASþRepl ¼ 1.01 3 107 for rs4780355; see Table S2
and Figure S5B). We further corroborated both association
signals by genotyping SNPs rs1250544 and rs4780355 in
additional sample sets fromGermany and Italy, comprising
2,360 CD cases and 1,015 healthy controls, but we also012
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The Amused summary statistics data of the two SNPs from the inde-
pendent GWAS on PS16 comprising 2,178 PS cases and
2,657 controls (panel E in Table S1, the same cases and
controls from the United Kingdom, as described in panel
C). In the combined analysis of discovery panels A
and B and replication panels D and E (Tables 3 and 4),
SNP rs4780355 achieved genome-wide significance
(pCDPS-GWASþRepl ¼ 1.37 3 1013) but also attained
genome-wide significance for CD alone (pCD-GWASþRepl ¼
4.99 3 108).
COMBINED Approach, Part 2: Meta-Analysis
Assuming Opposite-Direction Effects
An allele might confer a risk for CD while protecting
against PS and vice versa, as is the case for TYK2. Therefore,
we also screened our combined-phenotype meta-analysis
data (panels A and B) while coding alleles in such a way
as to consider the opposite effects of them in the two
diseases (see Subjects and Methods). We observed low
genomic inflation for the opposite-direction meta-analysis
(l1000 ¼ 1.009, Figure S3B). After excluding established
shared loci for PS and CD, the inflation factors further
decreased (Figure S3D). In a first step, we checked the
known risk SNP rs12720356 (TYK2; see Table 1) for oppo-
site direction of effects. SNP rs12720356 had a p value of
4.09 3 105 in the combined analysis of panels A and B
(Figure S4D); there was an odds ratio (OR) of 1.29 (95%
confidence interval [CI] [1.10,1.51]) for allele A in panel A
(pPS-GWAS ¼ 1.39 3 103) and of 0.78 (95% CI [0.65,0.94])
in panel B (pCD-GWAS¼ 1.013 102).We then selected three
SNPs for subsequent genotyping (with Sequenom) and
testing in replication panel D (see Table S1D). The selection
criteria were the same as for the same-direction effect meta-
analysis. However, none of the three SNPs replicated in
both diseases at p value < 0.05 (see Table S3).
In Silico Fine-Mapping: Refinement of Association
Signals of COMBINED Approach
For refinement of the association signals at ZMIZ1 and
SOCS1, we imputed a region of about 51 Mb around the
strongest signals from the discovery panels A and B (see
Table S1) by using the EUR reference from the 1000
Genomes Project45 (see Subjects and Methods). In silico
fine-mapping of the region around SOCS1 via standard
meta-analysis methodology (see Subjects and Methods)
confirmed rs4780355 to be highly significant in this region
(pGWAS ¼ 4.04 3 107). Additionally, another SNP,
rs2021511, which is located in the same intron as
rs4780355 (2.9 kb downstream of rs4780355) showed
the same magnitude of association (pGWAS ¼ 1.58 3 107;
Figure 2) but was not selected for further replication
because of the high linkage disequilibrium (LD) between
SNPs rs4780355 and rs2021511 (r2 ¼ 0.934) according to
the 1000 Genomes Project EUR reference. Screening of
the imputed region of SOCS1 for coding SNPs revealed
one missense SNP with p < 104 within the TNP2 gene,
namely rs11640138. We genotyped this SNP in replicationerican Journal of Human Genetics 90, 636–647, April 6, 2012 641
Table 3. Association Results of Combined-Phenotype Meta-Analysis Considering Same-Direction Effects of Alleles from COMBINED
Approach
Chr SNP A1 Locus
CDþPS Discovery
GWAS (4,671/10,460)
PS GWAS
(2,529/4,955)
CD GWAS
(2,142/5,505)
PS Replication
(3,187/4,759)
CD Replication
(4,073/2,478)
p OR p OR p OR p OR p OR
10 rs1250544a G ZMIZ1 1.12 3 1005 1.13 3.85 3 1005 1.18 3.31 3 1002 1.09 1.94 3 1004 1.14 5.28 3 1007 1.22
10 rs1250560b A ZMIZ1 3.13 3 1006 0.87 4.31 3 1006 0.82 4.87 3 1002 0.92 1.06 3 1003 0.87 8.06 3 1010 0.79
10 rs1250559b A ZMIZ1 1.53 3 1007 0.87 4.58 3 1006 0.82 3.46 3 1002 0.91 1.16 3 1003 0.87 4.10 3 1010 0.79
16 rs4780355a T SOCS1 9.36 3 1007 1.16 1.72 3 1004 1.18 1.47 3 1003 1.15 7.53 3 1004 1.14 7.40 3 1006 1.19
The following abbreviations are used: Chr: chromosome of marker; SNP: rs ID; A1: minor allele; Locus: one candidate gene in the region; p/OR: p value and
corresponding odds ratio with respect to minor allele for the combined-phenotype GWAS meta-analysis of CD and PS (panels A and B), GWAS meta-analysis
of PS (panel A), GWAS meta-analysis of CD (panel B), PS replication analysis (as part of panel D), CD replication analysis (part of panel D, panel E). For each panel,
numbers of cases/controls are displayed in parentheses. None of the SNPs showed an exact Hardy-Weinberg p value < 0.01 in the PS and CD replication panels
(panels D and E).
aSNPs were identified via genotype imputation based on the HapMap3 reference and P/OR are given according to that analysis.
bSNPs were identified via genotype imputation based on the 1000 Genomes reference and P/OR are given according to that analysis.panel D, but it did not replicate in either disease at
p value < 0.05.
In silico fine-mapping of ZMIZ1 with the same method-
ology narrowed down the association signal to two coding
SNPs, namely rs1250559 (pCDPS-GWAS ¼ 1.53 3 107,
Figure 2) and rs1250560 (pCDPS-GWAS ¼ 3.13 3 106).
According to the 1000 Genomes Project EUR reference,
both SNPs are in near perfect LD (r2 ¼ 0.948). Depending
on different splice variants of ZMIZ1, rs1250559 is either
intronic or located in the 3-untranslated region (3-UTR),
whereas rs1250560 is either an intronic SNP or a missense
SNP located in exon 5. The intronic ZMIZ1 SNP rs1250544,
which yielded the strongest signal from the initial
same-effect combined-phenotype meta-analysis, and the
missense SNP rs1250560 are 20.6 kb apart and in moderate
LD (r2 ¼ 0.682). In order to substantiate our findings from
the in silico analyses, we genotyped both ZMIZ1 SNPs in
replication panels D and E (see Table S1). As shown in
Tables 3 and 4, both SNPs were associated with PS at the
0.05 level and even showed genome-wide significance with
CD (pCD-Repl ¼ 8.06 3 1010 at rs1250560, pCD-Repl ¼
4.10 3 1010 at rs1250559). Interestingly, the association
signals of these two SNPs were much stronger in the initial
analysis of PS panel A than of CD panel B. The combined
analysis of discovery panels A and B and replication panelsTable 4. Association Results of Combined-Phenotype Meta-Analysis C
Approach
Chr SNP A1 Locus
PS GWAS and
Repl (5,716/9,714)
CD G
Repl
p OR p
10 rs1250544a G ZMIZ1 3.53 3 1008 1.16 2.56 3
10 rs1250560b A ZMIZ1 3.03 3 1007 0.84 4.10 3
10 rs1250559b A ZMIZ1 3.63 3 1007 0.84 1.24 3
16 rs4780355a T SOCS1 5.30 3 1007 1.15 4.99 3
For abbreviations used, see Table 3. Combined analysis of PS GWAS meta-analysis
meta-analysis (panel B) and CD replication (part of panel D, panel E), combined a
(panels D and E).
aSNPs were identified via genotype imputation based on the HapMap3 reference
bSNPs were identified via genotype imputation based on the 1000 Genomes refe
642 The American Journal of Human Genetics 90, 636–647, April 6, 2D and E yielded genome-wide significance for rs1250560
(pCDPS-GWASþRepl ¼ 7.34 3 1016) and rs1250559
(pCDPS-GWASþRepl ¼ 2.78 3 1016), both of which are of
higher significance than was observed for rs1250544
(pCDPS-GWASþRepl ¼ 7.32 3 1014) (Tables 3 and 4).
Effect on Gene Expression
We subsequently assessed a potential functional effect of
the four SNPs showing association for both CD and PS
with the same direction of effects, namely rs1250544,
rs1250559, rs1250560 (ZMIZ1), and rs4780355 (near
SOCS1). To this end, we investigated the correlation of
SNP genotypes with gene expression levels by means of
in silico expression quantitative trait locus (eQTL) analysis
byusing themRNAbySNPBrowser software.47 This program
utilizes genotype data from 408,273 SNPs and
gene expression data from Epstein-Barr-virus-transformed
lymphoblastoid cell lines that were collected from 400 chil-
dren and measured with the Affymetrix HG-U133 Plus 2.0
chip. Significant evidence (uncorrected pExpression < 10
4)
for causing differential expression of ZMIZ1 was observed
for SNP rs1250546 (prs1250546 ¼ 8.10 3 105), which is in
high LD with our lead SNP rs1250544 (r2 ¼ 0.829). Also,
we found an even stronger evidence for association
between expression of C16ORF75 (MIM 612426), which isonsidering Same-Direction Effects of Alleles from COMBINED
WAS and
(6,215/7,983)
CDþPS GWAS and
Repl (11,931/17,697)
Status NowOR p OR
1007 1.16 7.32 3 1014 1.16 PS, CD-PS, CD
1009 0.84 7.34 3 1016 0.85 CD-PS, CD
1009 0.84 2.78 3 1016 0.85 CD-PS, CD
1008 1.17 1.37 3 1013 1.16 CD-PS, CD
(panel A) and PS replication (part of panel D), combined analysis of CD GWAS
nalysis of CDþPS GWAS meta-analysis (panels A and B) and CDþPS replication
and p/OR are given according to that analysis.
rence and p/OR are given according to that analysis.
012
Figure 2. Regional Association Plots of In Silico
Fine-Mapping for Newly Detected Shared Risk
Loci from COMBINED Approach
Shared risk loci for CD and PS at (A) 10q22
(ZMIZ1) and (B) 16p13 (near SOCS1). eQTL anal-
yses revealed a potential effect of the associations
at ZMIZ1 and near SOCS1 on gene expression. p
values (log10p) are depicted with regard to the
physical location of markers and are based on
imputed genotypes. SNP genotypes were im-
puted with the EUR reference from 1000
Genomes Project45 (see Subjects and Methods).
The following abbreviations are used: blue-filled
circle, lead SNP of the combined-phenotype
data (panels A and B); other filled circles,
analyzed SNPs of the combined-phenotype data
(panels A and B) where the fill color corresponds
to the strength of linkage disequilibrium (r2) with
the lead SNP (for color coding see legend in the
upper right corner of each plot); green triangles,
analyzed SNPs of the meta-analysis on PS (panel
A); gray squares, analyzed SNPs of the meta-anal-
ysis on CD (panel B); and blue line, recombina-
tion intensity (cM/Mb). Positions and gene anno-
tations are according to NCBI’s build 37 (hg19).located 90 kb upstream of SOCS1, and SNP rs243323
(prs243323 ¼ 1.10 3 108). This SNP is also in high LD with
our lead SNP rs4780355 (r2 ¼ 0.931). Both proxy SNPs
rs1250546 and rs243323 were also significantly associated
in our same-effect combined-phenotype analysis of dis-
covery panels A and B (pGWAS¼ 7.153 105 for rs1250546,
pGWAS ¼ 1.80 3 106 for rs243323). This in silico eQTL
analysis supports the notion that our four reported SNPs
might affect the expression of ZMIZ1 and C16ORF75. The
full list of significant associations between SNP genotypes
and gene expression levels is shown in Table S4.Discussion
In a large combined sample set of 6,215 CD cases, 8,644 PS
cases and 20,560 healthy controls, we have identified
seven non-HLA susceptibility loci shared between CD
and PS (9p24 near JAK2, 10q22 at ZMIZ1, 11q13 near
PRDX5, 16p13 near SOCS1, 19p13 near FUT2, 17q21 atThe American Journal ofSTAT3, 22q11 at YDJC). These loci, except
for SOCS1, were already known to play a
role in CD etiology, but were of unknown
significance for PS13 (see also Table S5 for
associations with other diseases). Notably,
three of these loci showed genome-wide
significance when tested for association
with PS alone (10q22 at ZMIZ1, 11q13
near PRDX5, and 22q11 at YDJC). Further-
more, we revealed a risk locus for CD
(16p13 near SOCS1). The identified shared
risk loci point to functionally very inter-
esting genes that might play a role in the
pathogenesis of both CD and PS. The geneZMIZ1 (also known as hZIMP10 or TRAFIP10) encodes for
the protein zinc finger MIZ type 1, which is a member of
the protein inhibitor of activated STAT (PIAS) family. The
protein regulates the activity of several transcription
factors such as the androgen receptor, Smad3/4, and p53;
regulates TGF-b/SMAD signaling; and is induced by
retinoic acid.48 FUT2 encodes a-(1,2)fucosyltransferase
(FUT2), a physiological trait that regulates expression of
the Lewis human blood group of antigens on the surface
of epithelial cells and in body fluids. Genetic variants in
FUT2 have been implicated in susceptibility to infections
with Norovirus49 and Helicobacter pylori.50 PRDX5 encodes
Peroxiredoxin-5, which belongs to the peroxiredoxin
family of antioxidant enzymes that reduce hydrogen
peroxide and alkyl hydroperoxides and might play a
protective role during inflammatory processes. SOCS1
encodes the suppressor of cytokine signaling 1 (SOCS1),
a protein that is member of the STAT-induced STAT inhib-
itor (SSI), also known as suppressor of cytokine signaling
(SOCS) family. SOCS1 is a cytokine-inducible negativeHuman Genetics 90, 636–647, April 6, 2012 643
Figure 3. Gene Relationships across the 11 Shared Risk Loci of CD and PS Identified by GRAIL Analysis
GRAIL46 is a statistical text-mining approach to quantify the degree of relatedness among genes in genomic disease regions. It estimates
the statistical significance of the number of observed relationships with a null model in which relationships between the genes occur by
random chance. A significance score ptext, which is adjusted for multiple hypothesis testing, represents the output GRAIL score. ptext
values approximately estimate type-I error rates. Outer circle: lead SNPs from shared risk loci of both diseases; each box represents
a SNP. Inner circle: genes of the genomic regions around lead SNPs that were identified based on LD properties; each box represents
a gene; genes that were scored at ptext < 0.05 are significantly linked to genes in the other disease regions and are indicated in bold
type. Lines: the lines between genes represent significant connections, with the thickness and redness of the lines being inversely
proportional to the probability that a text-based connection would be seen by chance.regulator of cytokine signaling.51,52 Cytokines such as IL2,
IL3, erythropoietin, and interferon-gamma can induce
expression of SOCS1.53 Moreover, a potential functional
effect of the associations at ZMIZ1 and near SOCS1 on
gene expression was found by an in silico eQTL analysis.
The present study has increased the number of known
shared CD and PS susceptibility loci to eleven (IL12B,
IL23R, REL, TYK2, JAK2, ZMIZ1, PRDX5, SOCS1, STAT3,
FUT2, and YDJC). To quantify the degree of relatedness
between genes within the eleven loci, we used a published
statistical genomicsmethod, namely GRAIL (gene relation-
ships across implicated loci),46 that applies statistical text
mining to PubMed abstracts (see Subjects and Methods
and Figure 3). GRAIL highlights a number of nonrandom
and evidence-based connections between the genes within
the nine loci that might indicate overlap in the pathways
acting in the etiology of CD and PS. Multiple genes
(IL12B, IL23R, TYK2, JAK2, SOCS1, and STAT3) are644 The American Journal of Human Genetics 90, 636–647, April 6, 2involved in IL23/Th17 signaling and play a critical role
in the principal signaling mechanism for a wide array of
cytokines and growth factors. It is noteworthy that genes
CDC37 ([MIM 605065] 21.7 kb downstream of the estab-
lished shared risk locus at TYK2) and STIP1 ([MIM
605063] 113.5 kb upstream of the identified shared risk
at PRDX5) were found by GRAIL to be significantly con-
nected. CDC37 and STIP1 encode CDC37 and STI1, respec-
tively, two of several auxiliary proteins that associate with
the heat-shock protein 90 (HSP90) molecular chaperone
and thus are collectively referred to as HSP90 cochaper-
ones.54 HSP90 itself is an abundant, evolutionarily con-
served molecular chaperone that acts mainly as a cofactor
for the folding of polyproteins into functional, stable,
mature proteins, and it physically associates with JAK1
and probably JAK2,55 demonstrating that JAK1/2 are
client proteins of HSP90. A study in mice and in patient
samples suggested that HSP90 inhibitors might help treat012
JAK2-dependent myeloproliferative neoplasms (MPNs).56
Moreover, inhibition of HSP90 was found to block Nod2-
mediated activation of the transcription factor NF-kB and
reduce NALP3-mediated gout-like inflammation in
mice,57 and mutations in the gene encoding NALP3, a
member of the Nod-like receptor (NLR) protein family,
are associated with several autoinflammatory disor-
ders.58,59 Our hypothesis that CDC37 and STIP1 are poten-
tial joint risk factors for CD and PS is substantiated by an
association peak within CDC37 in our same-effect com-
bined-phenotype analysis of discovery panels A and B
(pGWAS ¼ 1.61 3 103 for rs11879191, Figure S6).
It is worth noting that we used a two tier strategy to iden-
tify shared disease risk loci: Both approaches turned out to
be effective and complementary tools for gaining insights
into the postulated shared pathogenesis of CD and PS.
Application of only a single strategy would have decreased
the number of identified loci. Although the OVERLAP
approach represents a simple and cost-effective strategy
(cross-disease comparison of known risk SNPs), the
COMBINED approach provides the power to identify
shared susceptibility loci even if association signals are
heterogeneous between diseases, that is the particular
SNP showing the smallest p value at the considered locus,
as was the case, for example, for the identified risk locus at
ZMIZ1. This heterogeneity of most strongly associated
SNPs could be due to interactions with other genetic
variants or environmental factors, to differences in the
distribution or effect size of causal alleles, or to the fact
the identified SNPs show an association signal only
because they are in LD with the actual causal variant. In
particular, the increase of power due to increased sample
sizes makes the COMBINED approach a potentially power-
ful tool to detect shared risk loci that might be missed in
disease-specific GWASs that are often underpowered
because of their comparatively smaller sample sizes.
Because we did not search for loci harboring association
signals with different and independent SNPs in terms of
LD associated with CD and PS, there is room for improve-
ment. For instance, in a simple rank approach with regard
to single-marker associationpvalues, different disease-asso-
ciated markers for the same locus could be determined
when they rank high with regard to their p value in associ-
ation scans of CD and PS, respectively. This would allow
detecting shared susceptibility loci even if association
signals are heterogeneous between diseases. An approach
tomeet the challenge of theheterogeneity of genetic effects
of the same markers between different diseases was
proposed by Morris et al.60 The authors developed a test of
association within a multinomial regression framework
and demonstrated the improved power of their multino-
mial regression-based analysis over existing methods.
It is likely that future studies will identify additional
shared disease loci for CD and PS by further increasing
the sample size of analyzed case-control panels or, for
example, by applying the suggested rank approach.
Evidence for a shared etiological basis among several auto-The Amimmune and inflammatory diseases is growing. For Crohn
disease, for example, Lees and colleagues currently re-
ported that 51 of the known 71 loci overlap with more
than 23 distinct diseases, comprising also several nonau-
toimmune conditions.61 Given the success of this study,
we expect the same for the investigation of further combi-
nations of such diseases for shared risk factors.Supplemental Data
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